摘要
来文报道应用我室制备的单克隆抗体(单抗)WLA2C4、CL-3、Ps-9及Ps-10,用酶联免疫ELISA结合抑制法分别测定了肺癌组及正常人组血清中癌相关抗原(TAA)的含量,并以组合方式将4株单抗分为2组测定肺癌患者血清TAA含量,其中一组还对呼吸系统良性病变患者56例进行了测定。结果表明,单株应用单抗与组合应用单抗检测正常人组及呼吸系统良性病变组血清TAA的检出率均不高,两者之间无显著差异。而单株使用单抗检测肺癌组TAA检出率分别为52%~55%,组合应用后其TAA检出率显著增高,WLA2C4与CL-3组的TAA检出率为79.3%,CL-3、Ps-9与Ps-10组的检出率为85.2%,显示了组合应用单抗良好的互补性。鉴于组合应用单抗的假阳性检出率与假阴性检出率之和小于30%,故有诊断价值。
In the present study, tumour-associated antigen (TAA) in the sera of lung cancer patients and normal subjects was determined by binding inhibition ELISA using monoclonal antibodies (McAbs) WLA2c4, CL-3, Ps-9 and PS-10 and 'cocktail' of two groups of the McAbs. In addition, sera from 56 patients with benign respiratory diseases were examined by 'cocktail' of one group of the McAbs. The results showed that TAA in normal controls and patients with benign respiratory diseases was very low whether with one McAb or 'cocktail' of McAbs. The positive rates in lung cancer patients for WLA2c4, CL-3, Ps-9, and Ps-10 ranged from 52% to 55%. When detected by 'cocktail' , the TAA positive rates were raised significantly: WLA2c4 with CL-3 and CL-3, and with Ps-9 and Ps-10 were 79.3% and 85.2%, respectively, suggesting a good complementary effect of the 'cocktail' . The sum of false positive rate and false netgative rate was less than 30%. Therefore, 'cocktailing' of McAbs is a method of great significance in diagnosis of lung cancer.
关键词
诊断
TAA
肺肿瘤
单克隆抗体
lung cancer
serum
antibody, monoclonal
turnout-associated antigen
diagnosis